uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

​uBriGene Biosciences has partnered with Cellinfinity BIO to advance the clinical development of in vivo CAR-T therapy programmes for haematologic and solid tumours.

The post uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
FDA approves Anumana’s pulmonary hypertension algorithm
Lantern receives FDA clearance for paediatric STAR-001 CNS trial
Novo Nordisk receives FDA approval for basal insulin Awiqli
Neurophet and ALZ-NET sign MoU on Alzheimer’s therapies

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us